Clinical Catalysts Driving Momentum, Plus an Oldie and a Newie
Denver, Colorado (www.247marketnews.com) – Clinical catalysts are driving the market, this morning, plus a mover we’ve been covering for weeks and a new runner.
Download the 24/7 Market News App here 24/7 Market News App or on the App Store.
NeOnc Technologies Draws Growing Wall St Attention Ahead of Brain Cancer Data Catalysts
NeOnc Technologies (NASDAQ:NTHI) has started gaining traction among biotech investors following a wave of analyst initiations, expanding institutional ownership, and continued insider accumulation as the company advances its central nervous system oncology pipeline. The clinical-stage biotech company is focused on novel therapies designed to overcome one of neuro-oncology’s biggest challenges; the blood-brain barrier.
Recent Wall Street coverage has significantly increased visibility around the company. Maxim Group initiated coverage with a “Buy” rating and a $20 price target, while Alliance Global Partners launched coverage with a “Buy (Speculative)” rating and a $13 price target. BTIG Research also entered coverage with BTIGa “Buy” rating and a $15 targe Research a “Buy” rating and a $15 target, underscoring growing analyst interest in NeOnc’s differentiated intranasal drug delivery platform targeting aggressive brain cancers.
Investor attention has also been fueled by substantial insider buying activity. CEO, Chairman, and President Amir Heshmatpour has reportedly purchased more than $500,000 worth of shares recently, with cumulative insider buying nearing $1 million over the past year. Market participants often monitor insider accumulation closely, particularly ahead of anticipated clinical readouts and regulatory milestones.
Institutional participation has continued expanding as well, with firms including Bank of America, State Street Corp, Barclays PLC, Westmount Partners, and Foundations Investment Advisors increasing positions in the company. The convergence of insider buying, institutional accumulation, and upcoming clinical catalysts has increased speculation surrounding the company’s Phase 2a study evaluating NEO100 in glioblastoma and other aggressive CNS tumors.
Immunovant Delivers Strong Rheumatoid Arthritis Data while Advancing Multiple Late-Stage Programs
Immunovant (NASDAQ:IMVT) became a major focus across the biotech sector after reporting encouraging preliminary Phase data for IMVT-1402 in difficult-to-treat rheumatoid arthritis patients. The company reported Week 16 ACR20 response rates of 72.7%, alongside ACR50 rates of 54.5% and ACR70 rates of 35.8%, results that investors are closely analyzing given the highly refractory patient population enrolled in the study.
The company stated that 86.7% of enrolled patients had failed at least two prior advanced therapies, highlighting the severity of disease in the trial population. Immunovant also confirmed that IMVT-1402 was observed to be safe and well tolerated with no new drug-related safety signals identified during the open-label portion of the study. Additional updates are expected later in 2026, including topline data from the fully enrolled cutaneous lupus erythematosus trial.
Beyond the rheumatoid arthritis program, Immunovant continues advancing potentially registrational studies in Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjögren’s disease. The company also announced that its current cash position of approximately $902.1 million is expected to provide runway through the potential commercial launch of IMVT-1402 in Graves’ disease.
Investors are also closely watching the company’s strategic pivot following the discontinuation of batoclimab after unsuccessful thyroid eye disease Phase 3 results earlier this year. Management indicated that operational and clinical learnings from batoclimab are being leveraged to accelerate development of IMVT-1402 across multiple autoimmune indications.
ImmunityBio Advances Toward Potential FDA Expansion for ANKTIVA
ImmunityBio (NASDAQ:IBRX) captured market attention after announcing that the FDA accepted its supplemental Biologics License Application for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer patients with papillary disease. The FDA assigned a PDUFA target date of January 6, 2027, marking a significant regulatory milestone for the company.
The supplemental filing seeks to expand ANKTIVA’s existing indication beyond carcinoma in situ patients to include papillary-only disease, which represents a substantially larger portion of the non-muscle invasive bladder cancer population. According to the company, approximately 85% of newly diagnosed NMIBC patients present with papillary disease.
Investor interest intensified following details from a recent FDA workshop where clinicians and scientific experts discussed the biological overlap between papillary disease and carcinoma in situ. The workshop discussions appeared to support the rationale behind ImmunityBio’s expansion strategy, with panelists reportedly acknowledging similarities in disease biology and real-world treatment practices.
The filing is supported by data from the QUILT 3.032 Phase 2/3 study, where the company reported a 12-month disease-free survival rate of 58.2%. Additional long-term metrics included progression-free survival of 82% at 36 months and cystectomy-free survival above 83% through three years, metrics the company believes demonstrate meaningful bladder preservation potential.
AmpliTech Group Secures Key Regulatory Certifications for 5G Infrastructure Rollout
AmpliTech Group (NASDAQ:AMPG) announced a major operational milestone after receiving both FCC and Canadian ISED certifications for its complete 5G Native Distributed Antenna System platform. The approvals clear the company for immediate commercial deployment across the United States and Canada.
The certifications cover the company’s full 5G hardware ecosystem, including Pico Radios, AC/DC Mother Hubs, and Cascading Hubs, allowing wireless carriers and enterprise customers to deploy fully integrated systems without requiring additional regulatory approvals. Management stated that the approvals significantly streamline deployment and integration processes for customers seeking indoor 5G expansion.
The company believes the certifications position it to capitalize on growing demand in Fixed Wireless Access and Private 5G markets. AmpliTech’s Native DAS platform is designed to improve signal coverage, power efficiency, and scalability across enterprise campuses, smart factories, logistics centers, healthcare systems, and defense applications.
Management also disclosed that the company has already received initial orders from a North American mobile network operator, with shipments expected to begin later this year. Investors are increasingly watching smaller 5G infrastructure companies as telecom operators continue accelerating next-generation network deployment initiatives.
POET Technologies Raises $400 Million To Accelerate AI Photonics Expansion
POET Technologies (NASDAQ:POET) remained a major market story after closing a massive $400 million registered direct offering aimed at accelerating its AI and data center infrastructure strategy. The financing was completed at $21 per share, above the company’s recent NASDAQ closing price, signaling strong institutional interest in the photonic interconnect developer.
The company said proceeds will be used to significantly scale manufacturing capacity, expand research and development, pursue acquisitions, and accelerate commercialization of its optical interposer platform. POET stated it is targeting roughly a ten-fold increase in wafer production and optical engine assembly capacity heading into 2027.
Investor excitement around the company continues to build as demand for AI infrastructure accelerates globally. POET’s technology is designed to improve bandwidth efficiency, reduce power consumption, and enable high-speed optical communication systems required for hyperscale AI clusters and next-generation data centers.
Management also highlighted expansion initiatives across Singapore and Malaysia while increasing global headcount above 115 employees. The company indicated that strategic partnerships and manufacturing agreements tied to AI optical networking demand are continuing to develop as the broader AI infrastructure race intensifies.
Micware Becomes One of the Market’s Most Active Recent IPOs
Micware (NASDAQ:MWC) emerged as one of the session’s most actively watched recent IPOs after rebounding sharply from fresh post-offering lows. Shares moved back above the company’s $8 IPO price after setting new lows, $4.10, yesterday.
The Japan-based software and IT solutions company focuses primarily on automotive and mobility technologies, sectors that continue attracting investor interest due to rapid autonomous driving, connected vehicle, and smart transportation trends. The company recently completed an upsized initial public offering of 2.85 million ADSs, generating approximately $22.8 million in gross proceeds.
Micware’s NASDAQ debut arrives during a period of heightened volatility in small-cap growth stocks, particularly recent IPOs. Traders are closely monitoring volume activity and price stabilization as the company begins establishing its public market trading history.
The company’s focus on automotive software development and mobility infrastructure places it within several rapidly evolving technology themes, including connected transportation systems, embedded vehicle software, and next-generation mobility platforms.
Download the 24/7 Market News App here 24/7 Market News App or on the App Store.
Sources and Links
• NeOnc Technologies SEC Filings
• Immunovant Investor Relations
• Roivant Investor Relations
• ImmunityBio Press Release
• ImmunityBio Official Website
• ANKTIVA Information
• POET Technologies Official Website
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For the full disclosure, please visit: https://go.247marketnews.com/nthi-disclosure/
For further information, please visit 247marketnews.com.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.